The hematologic oncology condition center is a comprehensive resource for clinical news and expert insights on hematologic oncology. Read more at OncLive.
June 11th 2025
The FDA has approved a tablet formulation of zanubrutinib for use in all 5 approved indications of the capsule formulation.
June 9th 2025
The FDA has lifted the partial clinical hold on a phase 3 study assessing IFx-2.0 in advanced Merkel cell carcinoma.
June 7th 2025
Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.
June 6th 2025
Experts highlight key abstracts to watch for at the 2025 EHA Congress.
June 5th 2025
Kanwarpal S. Kahlon, MD, discusses the implications of the availability of generic eltrombopag for immune thrombocytopenia and severe aplastic anemia.
Vivek Patel, MD, discusses the growing body of data supporting the use of bispecific antibodies in patients with relapsed/refractory follicular lymphoma.
Epcoritamab monotherapy yielded durable remissions and survival benefits in relapsed/refractory LBCL that remained in CR 2 years after starting treatment.
June 4th 2025
The FDA granted breakthrough therapy designation to iopofosine I 131 for relapsed/refractory Waldenström macroglobulinemia.
June 3rd 2025
The first CAR T-cell therapy designed for patients with relapsed/refractory AL amyloidosis showed feasibility and early efficacy and safety signals.
Brentuximab vedotin plus ECADD chemotherapy has been approved in Europe for adult patients with newly diagnosed, stage IIB to IV Hodgkin lymphoma.
Ziftomenib monotherapy elicited clinically meaningful, MRD-negative responses, including CRs, in heavily pretreated, relapsed/refractory NPM1-mutant AML.
June 2nd 2025
The FDA has granted priority review to ziftomenib for relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.
June 1st 2025
Glofitamab plus gemcitabine/oxaliplatin demonstrated improved PFS and OS compared with rituximab in patients with relapsed/refractory DLBCL.
May 31st 2025
Zilovertamab vedotin plus R-GemOx elicits responses in patients with relapsed or refractory diffuse large B-cell lymphoma.
May 30th 2025
Phase 1 data indicate that KITE-363 represents a promising therapeutic approach for patients with relapsed/refractory B-cell lymphoma.
PhasED-Seq–assessed ctDNA-based MRD negativity was strongly associated with improved PFS after frontline treatment in patients with DLBCL.
Read a recap of the episodes of OncLive On Air that debuted in May 2025.
May 29th 2025
Vivek Patel, MD, discusses the safety of bispecific antibodies and the choice between these agents and CAR T-cell therapy for follicular lymphoma.
Rituximab monotherapy delayed the time to next treatment vs watchful waiting in advanced stage, asymptomatic, low tumor burden follicular lymphoma.
May 28th 2025
Updated NCCN Guidelines recommend pemivibart in immunocompromised patients with B-cell lymphomas who are at higher risk of contracting COVID-19.